## GoTreatIT

## GTI laaja versio käyttöopas

Johanna Kärki Lastenreumatologi 1.11.2019 Päivitetty 7.10.2021 Tarkista, että GTI-versio on tämä

# GoTreatIT® Rheuma

CE NO986923993/0802-53288

www.diagraphit.com

COPYRIGHT © DIAGRAPHIT AS 2021

APPLICATION VE	RSION	V12.1.01	
DATABASE VERS	ION:	V30.0.0 (24	1.3.2020)
INSTALLATION D	DATE:	8.5.2007	
PATIENT ID VAL	DATION:	Personal II	) number (FI)
COUNTRY:	Finland		
LICENSED TO:	Central Finla	and Central H	lospital, Jyväskylä



### Yleisiä ohjeita

- Uuden tiedon syöttäminen aloitetaan + ESTABLISH/NEW REGISTRATION/PRESCIBE- kohdista
- Muista tarvittaessa vaihtaa <u>oikea päivämäärä</u> tapahtumalle
- Tiedot on aina syöttämisen ja muokkaamisen jälkeen <u>tallennettava</u> (SAVE)
- Lääkitys- ja diagnoosiosioita pääsee muokkaamaan/deletoimaan kuvaruudun oikeasta alakulmasta MEDICATION DETAILS ja DIAGNOSIS DETAILS- valikoista (EDIT/DELETE)

#### Uuden potilaan syöttäminen: New patient

SURNAME	FIRST NAME	DATE OF BIRTH	PERSONAL ID NUMBER (FI) (1	
TESTI	POTILAS	03.03.2003	030303A0303	
GENDER				тн
MALE	FEMALE	Dead		
				L
ETHNICITY		NATIVE COUNTRY		
White	Y	Timanu	Y	
Enable patient login (self	-serviced self assessment)			
<ul> <li>Allow patient login witho</li> </ul>	ut password	CHAQ Child (13-16v)		
Reset login password		Allow self assessment via	Web	
PATIENT ID:		<u> </u>	SAVE AND CLOSE CANCEL	
				<b>,</b>
		4.1		<b>A</b>

#### Potilaan valinta: Surname/Select

	SEARCH PA	TIENT		
	TESTI	Q		
SURNAME	FIRST NAME	PERSONAL ID NUMBER	PATIENT ID	DATE OF BIRTH
TESTI	FORSSA	050505-0505	386	05.05.1905
TESTI	HÄMEEMLINNA	080808-0808	385	08.08.1908
TESTI	HÄMEENLINNA	010101-0101	378	01.01.1901
TESTI	POTILAS	030303A0303	411	03.03.2003
TESTI	RIIHIMÄKI	060606-0606	381	06.06.1906
TESTI	TARJA	020202A0202	423	02.02.2002
TESTI	TESTI	080808A0808	424	08.08.2008
TESTINEN	HÄMEENLINNA	070707-0707	384	07.07.1907
TESTINEN	HÄMEENLINNA	020202-0202	379	02.02.1902
SORT BY SURNAME SORT BY DATE OF BIRTH		<b>Contact patient</b>	📥 Self rep	orted via web
+ NEW PATIENT CHANGE PATIENT DATA DATE 31.10.20	19 V BLOCK ACCESS			SELECT CLEAR

🙏 Q Search	DIAGN.DATA 👻 DISEASE ACT. 👻	HEALTH STATUS - INTERVENTION	I▼ QUALITY OF LIFE ▼ DAMAG	GE - GRAPHICS COMORBID	ITY - EVEN
	DIAGNOSE	S			
CURRENT DIAGNOSIS			NOTES (N)	STATUS (S)	
DEBUT DATE	DIAGNOSIS	STATUS	I Established		
12.4.2021	JIA Oligoarthritis (Persistent) (M084)	3	Reoccurring	– No info	
6.10.2020	Juvenile Idiopathic Arthritis (M089)	3	x Ceased +/- Status changed	1 Not sur	e v
			0 Remission	3 Verified	
			? Other		
+ ESTABLISH	CEASE CHANGE STATUS	SELEC			
DIAGNOSIS HISTORY			DIAGNOSIS DETAILS		
DEBUT DATE	DIAGNOSIS	CESS. DATE NOTES	Juve	enile Idiopathic Arthritis (M089	)
12.4.2021	JIA Oligoarthritis (Persistent)		DATE SY	F MPTOM START S N CLINICAL	REASON/ DIAGNOSIS DAT
6.10.2020	Juvenile Idiopathic Arthritis		6.10.2020	7.2020 <b>3 I</b> 6	.10.2020
			COMMENT		

## Diagnoosin (JIA+ alatyyppi, kumpikin erikseen) syöttö: Establish/Joint disorder/Juvenile Idiopathic Arthritis/Save



				ESTABLISH					
Juv	venile Idiopa	athic Art	hritis						
	<ul> <li>Joint dis</li> <li>⊙ Spi</li> <li>Osi</li> <li>Sei</li> <li>⊕ Un</li> <li>⊙ Un</li> <li>⊙ Un</li> <li>⊙ Un</li> <li>∑uv</li> </ul>	order ondyloart teoarthriti specified JIA Sys JIA Oli JIA Oli JIA Po JIA Po JIA Po JIA En JIA En JIA Un vstal Arthr indromic	hritis s tis <u>Arthritis</u> <u>pathic Arthritis</u> stemic Arthritis igoarthritis (Persist igoarthritis (Extend lyarthritis (RF Neg lyarthritis (RF Posi oriatic Arthritis thesitis Related Arth differentiated Arth ritis rheumatism	tent) ded) ative) tive) thritis mitis			Search	Q	
STA	TUS		ICD CODE	SYMPTOM START DAT	E CLINICAL DI	AGNOSIS DATE			
3	Verified	$\sim$	M089	7.2021	6.10.2021	$\sim$			
сом	MENT	l							
		6 10 2021							CEI

#### Klikkaa Juvenile Idiopathic Arthritis aktiiviseksi/Select

	DIAGNOSE	ES							
CURRENT DIAGNOSIS			NOT	TES (N)	2	TATUS	(5)		
DEBUT DATE	DIAGNOSIS	STATUS							
17.03.2019	Juvenile Idiopathic Arthritis	3		<ul> <li>Established</li> <li>Reoccurring</li> </ul>		_	No infe	0	
17.03.2019	JIA Undifferentiated Arthritis	3	3	x Ceased		1	Not su	ire	
			+	<ul> <li>+/- Status chang</li> <li>Remission</li> </ul>	ed	2	Probab	oly	
				! Diagnosisch	anged	0	venne	u	
+ ESTABLISH	CEASE CHANGE STATUS	SELECT		? Other					
DIAGNOSIS HISTORY			DIA	GNOSIS DETAI	LS				
DEBUT DATE	DIAGNOSIS	CESS. DATE NOTES		:	Juvenile Idiopa	thic	Arthr	itis	
17.03.2019	Juvenile Idiopathic Arthritis			DATE	SYMPTOM STAR	5	N	REASON	
17.03.2019	JIA Undifferentiated Arthritis			17.03.2019		3	I		
			(	COMMENT					
GRAPHICS				EDIT	DELETE				

#### Diagn.data/Extended ILAR JIA criteria

Θ		DIAGN	IOSIS	S DATA				
SYMPTO	OM DEBUT DATE	SYMPTOM AT DEBUT			CLINICAL DIAGNOSIS	DATE	DIAGNOSIS DAT	E
13.05.	.2019 🗸	polvi turvoksissa			01.06.2019	$\sim$	31.10.2019	$\sim$
					(Ext. ILAR JIA crit. no	t fulfilled)	(Ext. ILAR JIA c	rit. fulfilled)
EXTENDE	ED ILAR JIA CRITE	ERIA					HISTORY	
					ITIE	*		
				PSOKIATIC AKTEK				
	LASSIFICATION CRI	TERIA		CLASSIFICATION CRIT	ERIA			
A	Arthritis AND Enthesiti	S		Arthritis AND Psoriasis				
0	)R			OR				
	Arthritis			Arthritis and at least 2	of the following:			
	OR			Dactylitis				
	Enthesitis			Nail pitting or ony	holysis			
	with at least 2 of	the following:		Psoriasis in a first-	degree relative			
	The presence of o tenderness and/o pain	or a history of sacroiliac joint r inflammatory lumbosacral		SPECIFIC EXCLUSION	CRITERIA: B. C. D. E	-		
	The presence of F	H A-B27 antigen		UNDIFFERENTIATE	D ARTHRITIS	E		
	Onset of arthritis	in a male over 6 years of age		CLASSIFICATION CRIT	ERIA			
	Acute (symptoma	tic) anterior uveitis		Arthritis that fulfills crit	eria in no category (e.g.			
	History of ankylos	ing spondylitis, enthesitis		OR	ce of exclusion chiena)			
	USION CRITERIA	(ALL SPECIFIC CRITERIA MU	JST BE	ANSWERED 'NO' FOR	A CLASSIFICATION	то ве со	RRECT)	
A. F	Psoriasis or a history	of psoriasis in the patient or first-d	learee re	lative		Ye	es No	NA
B. 4	Arthritis in an HLA-B2	27 positive male beginning after th	e 6th bir	thday		Ye		NA
c. <sup>A</sup>	Ankylosing spondylitis Reiter's syndrome, or	s, enthesitis related arthritis, sacroi acute anterior uveitis, or a history	iliitis with of one o	n inflammatory bowel dise of these disorders in a firs	ase, t-degree relative	CY6	es No	NA
D. F	Presence of IgM rheu	matoid factor on at least 2 occasio	ns at lea	ast 3 months apart	_	Ye	es No	NA
E. F	Presence of systemic	JIA in the patient		-		Ye		NA

Э	DIAGNOSIS DATA		
SYMPTOM DEBUT DATE	SYMPTOM AT DEBUT	CLINICAL DIAGNOSIS DATE	DIAGNOSIS DATE
09.04.2018	Right knee pain	03.06.2019	17.09.2019 🗸
		(Ext. ILAR JIA crit. not fulfilled)	(Ext. ILAR JIA crit. fulfilled)

**Diagnoosipäivämäärällä** tarkoitetaan sitä päivämäärää, jolloin **artriitti on todettu ja hoito aloitettu** (paikallishoito/ p.o. kortisoni/ DMARD). GTI:ssä tämä merkitään kohtaan "**clinical diagnosis date**".

Diagnosis date = JIA diagnostisten kriteereiden täyttyminen.

#### Yleisnäkymä



#### Otsikkovalikko



#### Diagn.data/Diagnostic test-Lab Labrojen kirjaaminen (CCPAb, RF, HLAB27)

Search Q	DIAGN.DATA Y DISEASE ACT. Y H	EALTH STATUS * INTERVENTION * QUALIT	TY OF LIFE • DAMAGE • GRAPHICS	COMORBIDITY - EVENTS
CURRENT MEDIC Adalimumab (Humira)		DIAGNOSTIC TESTS	- LAB	
Methotrexate	ARTHRITIS VASCULITIS CTD	OTHER TESTS SCREENING CVD	EXECUTED TESTS	HISTORY
	RA ASSOCIATED IMMUNOLO	GICAL TESTS	(-) RF IgM	08 10 2021
	Antibodies against	(-) (+) VALUE	(-) CCP (-) Quantiferon	02.11.2019
	ССР	- 2	(-) 1-500	
DISEASE ACTIVITY 25.04.2021	Rheumatoid Factor	(-) (+) VALUE		
AJC(71) : 2	RF IgG			
ESR : 32	RF IgA			
JADAS(P)-27 :	RF IgM	- 7		
25.04.2021 JADAS(Ch)-27 : <b>8,7</b>	Waaler-test			
DIAGNOSIS	EROSIONS			
6.2019		(-) (+) VALUE		
Clin.diagnosis date	Erosions in hands/feet			
Diagn.date (Ext. ILAR JIA)	Method:	$\sim$	·	
17.09.2019 RF (IgM) : 7			COMMENT	
aCCP : 2	Erosions in other joints			
HEALTH STATUS 05.11.2019	GOUT			
		(-) (+) VALUE	GENETIC TESTS	
CHAQ (Ch) :	S-URAT		(-)	(+)
EXT. INJECTION 25.04.2021	Urate crystals in synovial fluid/tophu	s	HLA-B27	
Number of : 2			Shared Epitope	

Merkitse myös mitattu arvo, sekä positiivinen että negatiivinen, kohtaan VALUE

#### Diagn.data/Diagnostic test-Lab Labrojen kirjaaminen: ANA, ENA, DNAAb

D ASSOCIATED IMMUNO				EXECUTED TESTS	IIISTORY
	LOGICAL TESTS			(+) ANA	01.04.2016
Antibodies against	(-) (+)	VALUE		(-) CCP	01.07.2015
ANA		1280	<u> </u>	(-) Quantiferon	01.07.2013
DNA					30.03.2015
Centromer			E		
ENA					
SSA		240			
SSB		320			
Anti-Smith					
RNP					
5CL-70					
Jo-1					
Smooth muscle					
Mitochondria				COMMENT	
CENP-A			-		
CRETION TESTS	(-) (+)	VALUE			
Schirmer's test right eye				GENETIC TESTS	
Schirmer's test left eye				(-)	) (+)
Saliva test				HLA-B27	

Merkitse myös mitattu arvo, sekä positiivinen että negatiivinen, kohtaan VALUE

#### Diagn.data/Diagnostic test-Lab Labrojen kirjaaminen (TbIFNg, ELISPOT)

		DIAGNOSTIC TESTS	S - LAB	
	ARTHRITIS VASCULITIS CTD OTH	IER TESTS SCREENING CVD	EXECUTED TESTS	HISTORY
	TUBERCULOSIS TESTS		(-) Quantiferon	02.11.2010
		(-) (+) VALUE	(-) T-Spot	02.11.2019
THEN	Mantoux			
IDIFING	Quantiferon			
ELISPOT	T-Spot			
	Rtg thorax			
	IMMUNOGLOBULIN			
		(-) (+) VALUE		
	IgG			
	IgA			
	IgM			
	VIRUS TESTS			
		(-) (+) VALUE		
	Hepatitis B core antibody		COMMENT	
	Hepatitis Bsurface antibody			
	Hepatitis B surface antigen			
	Hepatitis C antibody			
	HIV		GENETIC TESTS	
			(-)	(+)
			HLA-B27	
			Shared Epitope	

# Disease act/JADAS + Iriitti + kynsimuutokset + daktyliitit



#### JADAS:

- Aktiivit nivelet (klikkaa nivelukkoon
- ESR = Lasko
- CRP
- Inv.global = Lääkärin VAS niveltaudin aktiivisuudesta
- Child global = potilaan yleis-VAS
- Parent global = Vanhemman arvioimana lapset yleis-VAS

#### IRIITTI:

- Lähin silmälääkärin tarkastus
- Oikea/vasen silmä (solut)
- Akuutti/krooninen

## Health status/CHAQ (Child/Parent)+ Patient self assessment

	HEALTH STA	TUS (CHAQ CHILD)		
CHAQ PART 1	CHAQ PART 2 CHAQ PART 3 PATIENT SELF	ASSESSMENT		HISTORY
		WITHOUT ANY DIFFICULTY	H MUCH UNABLE TO NOT ICULTY DO APPLICABLE	22.09.2019
Are you able to	dress, including tying shoelaces and doing buttons?	0		17.09.2019
Are you able to	shampoo your hair?	0		06.05.2019
Are you able to	remove socks?			15.10.2018
Are you able to	cut fingernails?			25.06.2018
Are you able to	stand up from a low chair or floor?			05.04.2018
Are you able to	get in and out of bed?			19.03.2018
Are you able to	cut your meat?	0		
Are you able to	lift a cup or glass to mouth?	0		
Are you able to	open a new cereal box?	0		
Are you able to	walk outdoors on a flat ground?	1		
Are you able to	climb up five steps?	1		
AIDS OR DEV	ICES		HELP FROM ANOTHER PERSON	SCORE
Walker Crutches Wheelchair	<ul> <li>Special or built-up chair</li> <li>Built up pencil or special utensils</li> <li>Other</li> </ul>	pun, long-landred shoe norfl, etc.)	Arising Eating Walking	CHAQ (Ch) 0 (0-3) 0

## Health status/CHAQ (Child/Parent)+ Patient self assessment + koululiikunta

	HEALTH S	TATUS (CHAQ CHII	LD)	
HAQ PART 1 CHAQ PART 2	CHAQ PART 3 PATIENT S	ELF ASSESSMENT		HISTORY
PAIN 45 mm	JOINT PAIN 30 mm	BACK PAIN 20 mm	BACK PAIN AT NIGHT	22.09.2019 <b>17.09.2019</b> 06.05.2019
FATIGUE	RHEUMATIC ACTIVITY	MORNING STIFFNESS	CHANGE OF CONDITION	15.10.2018
30 mm	mm	1,00 🗸 hours	Worse 🗸	25.06.2018
PHYSICAL EXERCISE			PATIENT SATISFACTION	05.04.2018
3 or more times per week	k	$\sim$	Worse 🗸	19.03.2018
PASS1	PASS2	MCII	SPORTS AT SCHOOL	
×	$\sim$	$\sim$	I partly participate in sports $\searrow$	
RAPID3				
(0-30)	(0-10)	SEVERITY		
MM mm	CHILD GLOBAL cm			
COMMENT				SCORE
				CHAQ (Ch) 0,875 (0-3) 0,875

#### Health status/MDHAQ: FN/PS (käytössä aikuispuolella, sopii nuorisopolille))

HEALT	'H STATUS	(MDHAQ)			
MDHAQ PATIENT SELF ASSESSMENT					HISTORY
Over the last week, were you able to	WITHOUT ANY DIFFICULTY 0	WITH SOME DIFFICULTY 1	WITH MUCH DIFFICULTY 2	UNABLE TO DO 3	22.09.2019
					17.09.2019
dress yourself, including tying shoelaces and doing buttons?	0				06.05.2019
get in and out of bed?	0				15.10.2018
lift a full cup or glass to your mouth?	0				25.06.2018
walk outdoors on flat ground?		1			05.04.2018
wash and dry your entire body?	0				19.03.2018
bend down to pick up clothing from the floor?	0				
turn regular faucets on and off?		1			SCORE
get in and out of a car?	0				M-HAO(0-3) 0,25
walk 2 miles (3 km)?		1			
participate in sports and games as you would like?		1			(0-3) (0,4
get a good night's sleep?			2		MDHAQ (PS) (0-3) 1,25
deal with the usual stresses of daily life?		1			HAQ(0-3)
deal with feelings of anxiety or being nervous?		1			Βαινι ΗΔΟ
deal with feelings of depression or feeling blue?		1			(0-24)

#### Health status/pain catastrophizing

)	PAIN CATASTROPHIZING	3	
PAIN CATASTROPHIZING			HISTORY
When I feel pain			22.09.2019
It is terrible and I feel it is	never going to get any better.		
0	2 3 4	5 6	
Never do that	Sometimes do that	Always do that	
I feel I can't stand it anym	ore.		
t o	2 3 4	5 6	
Never do that	Sometimes do that	Always do that	
			SCORE Score 2 (0-6) 2

### Health status/Cigarette smoking

OBARETTE	SMOKING	
CIGARETTE SMOKING		HISTORY
Do you smoke cigarettes?	Yes No	22.10.2019
Have you smoked cigarettes before?	Yes No	22.09.2019
At what age did you start smoking?	14 years	
At what age did you stop smoking?	years	
How much do/did you typically smoke?	Less than a half 20-pack a day	
		SCORE
		CIGARETTE 0,8 PACK YEARS 0,8

### Health status/Using snuff

US	SING SNUFF	
USING SNUFF		HISTORY
Do you use snuff regularly? Have you used snuff before?	Yes Ves	No 22.10.2019 22.09.2019 No
At what age did you start using snuff?	13 years	
At what age did you stop using snuff?	years	
		SCORE
		SNUFF YEARS 4

### Intervention/Medication = Lääkitys

URRENT MEDICA	TION				ADM. COMMENT
START DATE	DRUG	DOSE	INTERVAL	ADM	
25.04.2017	Etanercept (Enbrel) (mg)	50	Once a week	SC	COMMENT
21.04.2016	Sulfasalazine (mg)	2000	Every day	PO	
	Nykylääkitys				NOTES (N)
Uusi lääl + prescri	KE LOPETUS ANNO BE CEASE CHANGE D		COMMENT DAT	A ENTRY	!     Adverse effect     I     Prescribed       0     No effect     +/-     Dose changed/given       *     Comment      >1 course       ?     Other     X     Cessation
IEDICATION HIST	ORY				MEDICATION DETAILS
START DATE	DRUG	CESSATI	ON DATE NOTES		Etanercept (Enbrel) (mg)
25.04.2017	Etanercept (Enbrel) (mg)				DATE DOSE INTERVAL N EFFICACY A
21.04.2016	Sulfasalazine (mg)				25.04.2017 50 Once a week I
04.05.2015	Methotrexate (mg)	21.04	.2016 !		Muokkaus
	Lääkityshis	storia			REASON ADVERSE EFFECT
MEDICATION GR	LOUPS				COMMENT

#### Lääkitys/Uusi lääke: Prescribe/Drug/Dose/Interval

Muista tarkistaa myös biologisen lääkkeen kauppanimi!



#### Lääkitys/Lääkkeen lopetus: Cease/lopetuksen syy

N		ADVERSE EFFECT		
RRENT MEDICATION	Methotrexate (m	⊕ ☐ Infections	Search	Q
START DATE DRUG		🕀 🗌 Cancer		
01.11.2019 Adalimumab (Hur	Adverse effect	Hematology		
07.06.2015 Folic acid (	No effect	⊕ _ Immunology		
	Costs	Endocrinology/metabolism		
7.06.2015 Methotrexat	Pregnancy	Orgen State S		
	Patient decision	🕀 🗌 Nervous system		
PRESCRIBE CEASE	Remission	🕀 🗌 Eyes		:
	Patient died	🕀 🗌 Ears		
ICATION HISTORY	Other Unknown	🕀 🗌 Cardiac/vascular system		
ART DATE DRUG	Infection	Respiratory system		
1.11.2019 Adalimumab (Hur	Other serious illne:	🕀 🗌 Nose		
7.06.2015 Folic acid (	Surgery Suboptimal efficac	⊖ _ GI tract		
	Relapse/increased	Diarrhea		
7.06.2015 Methotrexate	weight increased/	✓ Nausea		
	EFFICACY	Vomiting 01.11.2019		
		Colitis		
	COMMENT	Abdominal pain		
		Acute pancreatitis		
	USER	🕀 🗌 Mouth		
	johanna (Karki, Joh			
		OK Cancel		
	CESSATION DATE			

#### Lääkitys/Annoksen tai annostelutavan muutos: Change dose

RRENT HEDICATION  START DATE DRUG DOSE INTERVAL ADM  COMMENT  COMM	)	MEDICA	TION				
START DATE       DRUG       DOSE       INTERVAL       ADM         01.11.2019       Methotrexate (mg)       15       Once a week       PO       CHANGE DOSE         + PRESCRIBE       CCASE       MANCE DOSE       Methotrexate (mg)       ADM.       Subcutaneous         START DATE       DRUG       CEF       Methotrexate (mg)       ADM.       Subcutaneous         START DATE       DRUG       CEF       CHANGE EASON       SERUM CONCENTRATION         START DATE       DRUG       CEF       CHANGE REASON       SERUM CONCENTRATION         0.1.11.2019       Methotrexate (mg)       Methotrexate (mg)       SERUM CONCENTRATION         Patient decision       Modersion       Serum ConCENTRATION       SERUM CONCENTRATION         New Free       Contra week       Serum ConCENTRATION       SERUM CONCENTRATION         OL11.2019       Methotrexate (mg)       Serum ConCENTRATION       SERUM CONCENTRATION         OL11.2019       Methotrexate (mg)       Serum ConCENTRATION       SERUM CONCENTRATION         Subportion Concer       Other       Serum ConCENTRATION       SERUM CONCENTRATION         Other       Subportion Concer       Serum ConCENTRATION       SERUM CONCENTRATION         Subportion Concer       Subportion Concer       Serum	URRENT MEDICATION					ADM. COMMENT	
D1.11.2019       Methotrexate (mg)       15       Once a week       PO       COMMENT         CHANGE DOSE       CHANGE DOSE       Methotrexate (mg)       ADM.         CHANGE DOSE       Methotrexate (mg)       NEW DOSE       ADM.         EDICATION HISTORY       IS       mg       (Empty=not known)       Subcutaneous         START DATE       DRUG       CES       CHANGE REASON       SERUM CONCENTRATION         SERUM CONCENTRATION       Once a week       SERUM CONCENTRATION       SERUM CONCENTRATION         01.11.2019       Methotrexate (mg)       No effect       SERUM CONCENTRATION       SERUM CONCENTRATION         Near remission/no need       Pregnancy       Predient diedision       Near remission/no need       SERUM CONCENTRATION         Near remission/no need       Pregnancy       Student diedision       SERUM CONCENTRATION       SERUM CONCENTRATION         Unknown       Infection       Cancer       Other serious illness/condition       Surgery       Suboptimal efficacy       METHOD	START DATE	DRUG	DOSE	INTERVAL	ADM		
CHANGE DOSE	01.11.2019	Methotrexate (mg)	15	Once a week	РО		COMMENT
Methotrexate (mg)     START DATE     DRUG     CHANGE REASON     CHANGE REASON     CHANGE REASON     CHANGE REASON     SERUM CONCENTRATION     Once a week     CHANGE REASON     SERUM CONCENTRATION     SERUM CONCENTRATION     Costs   Comorbidity   Pregnancy   Patient decision   Mb decision   Methotrexate (mg)     Nue wer remission/no need   Patient died   Other   Infection   Singery   Subptimal efficacy						CHANGE D	OSE
NEW DOSE ADM.   EDICATION HISTORY IS   START DATE DRUG   O1.11.2019 Methotrexate (mg)     New remission   Once a week   Costs   Costs   Costs   Costs   Patient decision   Moder remission/no need   Patient died   Other serious illness/condition   Strand died   Strand died   Drug ANTIBODIES   Strand died   Strand died   Strand died   Once a week      Patient decision   MD decision   Drug ANTIBODIES   Strand died   Other serious illness/condition   Subporting efficacy   Coher serious illness/condition   Subporting efficacy   Charge matching				Methotrexat	æ (mg)		
PRESCRIBE CEASE CHANCE DOSE     15 mg        START DATE DRUG     01.11.2019 Methotrexate (mg)     15 mg        15 mg        15 mg        15 mg           15 mg        15 mg           15 mg                     15 mg                   15 mg  <				NEW DOSE			ADM.
START DATE DRUG   O1.11.2019 Methotrexate (mg)     Methotrexate (mg)     Image: Constance of the constance of	PRESCRIBE	CEASE	DOSE	15 mg	1	(Empty=not known)	Subcutaneous
START DATE       DRUG       CES         01.11.2019       Methotrexate (mg)       Adverse effect       SERUM CONCENTRATION         Adverse of efficacy       Costs       SERUM CONCENTRATION         Costs       Costs       REFERENCE AREA LEVEL         Pregnancy       Patient decision       MD decision         No driet       Unknown       Near remission/no need         Patient ded       Other       SERUM CONCENTRATION         Other       Unknown       Reference AREA LEVEL         Other serious illness/condition       Serum Concentration         Studeptimal efficacy       METHOD	EDICATION HISTORY			INTERVAL	DAY	WEEK MONTH	EFFICACY
START DATE     DRUG     CES     CHANGE REASON     SERUM CONCENTRATION       01.11.2019     Methotrexate (mg)     Adverse effect     SERUM CONCENTRATION       DRUG     Costs     Costs     REFERENCE AREA LEVEL       Dregnancy     Patient decision     DRUG ANTIBODIES       Patient died     SERUM CONCENTRATION       Other     Other     DRUG ANTIBODIES       DRUG Corcer     Other     SERUM CONCENTRATION       DRUG ANTIBODIES     SERUM CONCENTRATION     SERUM CONCENTRATION				Once a week		$\sim$	
01.11.2019       Methotrexate (mg)       Adverse effect       SERUM CONCENTRATION         No effect       Loss of efficacy       REFERENCE AREA LEVEL         Costs       Comorbidity       Representation         Pregnancy       Patient decision       DRUG ANTIBODIES         Patient died       SERUM CONCENTRATION         No effect       SERUM CONCENTRATION         Patient decision       DRUG ANTIBODIES         Patient died       SERUM CONCENTRATION         Other       Other         Infection       REFERENCE AREA LEVEL         Other serious illness/condition       REFERENCE AREA LEVEL         Other serious illness/condition       METHOD	START DATE	DRUG	CES!	CHANGE REASO	N		SERUM CONCENTRATION
Costs       REFERENCE AREA LEVEL         Pregnancy       Patient decision         MD decision       Remission         Remission       Patient died         Patient died       SERUM CONCENTRATION         Other       Infection         Infection       RefERENCE AREA LEVEL         Other       SERUM CONCENTRATION         Unknown       Infection         Surgery       METHOD         Suboptimal efficacy       METHOD	01.11.2019	Methotrexate (mg)		Adverse effe No effect Loss of effici	ect acy		SERUM CONCENTRATION
Patient decision         MD decision         Remission         Near remission/no need         Patient died         Other         Unknown         Infection         Cancer         Other serious illness/condition         Surgery         Surgery         Belance/increased disease artivity				Costs Comorbidity Pregnancy			REFERENCE AREA LEVEL
MD decision Remission Near remission/no need Patient died Other Unknown Infection Cancer Other serious illness/condition Surgery Suboptimal efficacy METHOD METHOD				Patient decis	ion		
Remission         Near remission/no need         Patient died         Patient died         Other         Unknown         Infection         Cancer         Other serious illness/condition         Surgery         Suboptimal efficacy         METHOD				MD decision			
Patient died     SERUM CONCENTRATION       Other     Unknown       Infection     REFERENCE AREA LEVEL       Other serious illness/condition     Surgery       Suboptimal efficacy     METHOD				Near remission	ion/no need		DRUG ANTIBODIES
Unknown Infection Cancer Other serious illness/condition Surgery Suboptimal efficacy METHOD METHOD				Patient died Other	iony no need		SERUM CONCENTRATION
Infection Cancer Other serious illness/condition Surgery Suboptimal efficacy METHOD METHOD				Unknown			
Other serious illness/condition       Surgery       Suboptimal efficacy       Relance (increased disease activity)				Infection			REFERENCE AREA LEVEL
Surgery Suboptimal efficacy METHOD				Other seriou	s illness/cor	ndition	
Suboptimal efficacy METHOD				Surgery			
Kolance/increased disease activity				Suboptimal	efficacy		METHOD
Weight increased/weight decreased				Weight incre	eased disea ased/weigh	se activity t decreased	

#### Lääkitys/pitoisuus ja vasta-aineet: Cease/Change dose

	CHANGE DO	DSE
RENT MEDICATION	Adalimumab (Humira) (mg)	
TART DATE	NEW DOSE	ADM.
1.11.2019 Adalimum	ab (I 40 mg (Empty=not known)	Subcutaneous
7 06 2015 Foli	INTERVAL DAY WEEK MONTH	EFFICACY
100.2015	Every week	
.06.2015 Meth	CHANGE REASON	
- PRESCRIBE CE	Adverse effect No effect Loss of efficacy	SERUM CONCENTRATION 0,2
CATION HISTORY	Costs Comorbidity	REFERENCE AREA LEVEL
	Pregnancy Patient decision MD decision	Below
.11.2019 Adalimum	ab (F Near remission/no need	DRUG ANTIBODIES
.06.2015 Foli	Patient died	SERUM CONCENTRATION
.06.2015 Metho	Unknown Infection	45 REFERENCE AREA LEVEL
	Other serious illness/condition Surgery	
	Suboptimal efficacy Relapse/increased disease activity	метнор
	Weight increased/weight decreased	×
	COMMENT	
	USER	
	johanna (Karki, Johanna)	×
	CHANGE DATE 01.11.2019 V	SAVE AND CLOSE CANCEL

#### Lääkitys/korjaus jo syötettyyn tietoon tai virhesyöttö

DIAGN.DATA -	EDIT / DELET	ТЕ	EVENTS -	
	Adalimumab (Humira) (mg)			
CURRENT MEDICA START DATE	40 mg (Empty=not known)			
01.11.2019	INTERVAL DAY WEEK MONTH Every 2. week	ADM. Subcutaneous	COMMENT	
07.06.2015	COMMENT			
07.06.2015	USER		d/given	
+ PRESCRI	johanna (Karki, Johanna)	$\checkmark$		
MEDICATION HIST	DELETE DATE 01.11.2019 V	SAVE AND CLOSE CANCEL	(mg)	
01.11.2019	Adalimumab (Humira) (mg)	DATE DOSE INTERVAL N	EFFICACY ADM	
07.06.2015	Folic acid (mg)	01.11.2019 40 Every 2. week I	sc	
07.06.2015	Methotrexate (mg) ! +/-			
		REASON ADVERSE EFF	:CT	
		COMMENT		
MEDICATION GRO	DUPS			
✓ BIOLOGICS ✓ DMARD	■ NSAID/COXIB ✓ OTHER/SUPPLEMENTS	EDIT/DELETE	tanna)	

#### Intervention/Extended intra-articular injection=Paikallishoidot



#### Intervention/Extended intra-articular injection=Paikallishoidot



TORY		
DATE	NUMBER OF	DRUG
17.09.2019	5	Methylprednisolone
04.05.2019	7	Methylprednisolone
02.05.2016	1	Triamcinolone hexacetonide
30.07.2015	2	Triamcinolone hexacetonide
21.04.2015	2	Triamcinolone hexacetonide

Show accumulated values for selected drug

Show al	linjections

Show injections for selected date

#### Metyyliprednisolon

#### Intervention/Vaccination

VACCINATION		
VACCINATION		HISTORY
		02 11 2019
Hepatitis A		02.111.2017
Hepatitis B		
Hepatitis A+B	2010	
✓ Influenza	2012, 2013, 2015, 2016, 2017, 2018	
Pandemic influenza	2009	
Pneumococcal vaccine	13.9.2012	
MMR (measles, mumps and rubella)	9.2004, 3.2009	
Varicella	1.4.2010, 13.9.2012	
Varicella zoster		
Other vaccine		

#### Intervention/Physiotherapy

PHYSIOT		
		HISTORY
		22.10.2019
Do you regularly meet a physical therapist?	Yes No	22.09.2019
How many times a month do you get physical therapy?	2	
RENTS		
Does your child regularly meet a physical therapist?	Yes No	
How many times a month does your child get physical the	erapy?	

### Damage/Limited range of movements and erosions



### Comorbidity/Liitännäis- ja muut sairaudet

PATIENT JOURNAL USER HELP ADMIN	ESTABLISH	
DIAGN.DATA 🔻 DISEASE ACT. 👻 HEALTH STATUS 🐑 INTER	Chronic uveitis	
	<ul> <li>④ Infections</li> <li>④ Cancer</li> <li>Ø Hematology</li> <li>④ Immunology</li> <li>④ Immunology</li> </ul>	
DEBUT DATE COMORBIDITY	<ul> <li>Psychiatric disorder</li> <li>Psychiatric disorder</li> <li>Nervous system</li> <li>Eyes</li> <li>Visual disturbance</li> <li>Iridocyclitis/acute ant. uveitis</li> <li>Chronic uveitis</li> <li>Scleritis</li> <li>Retinopathy</li> <li>Cataract</li> </ul>	
CEASE CHANGE STATUS	Glaucoma Other eye disorder	
DEBUT DATE COMORBIDITY C	<ul> <li>♦ Respiratory system</li> <li>● GI tract</li> <li>● Skin</li> <li>● Musculoskeletal system</li> <li>● Urogenital tract</li> <li>● Inherited disorder</li> <li>● Pregnancy related</li> <li>● Injuries/poisoning/external causes</li> <li>Other</li> <li>None</li> <li>Unknown</li> </ul>	
	TOP30 ALL RHEUMA MANIFESTATIONS STATUS COMMENT ESTAI Verified	
GROUP ALL RHEUMA MANIFESTATIONS	DEBUT DATE 01.11.2019 V V ONGOING	

#### Comorbidity/Liitännäis- ja muut sairaudet

		ESTABLISH	
DIAGN.DATA - DISEA	\SE ACT. ▼ HEALTH STATUS ▼ INTE	Psoriasis	
URRENT COMORBIDITY	COMORBIDITY	Aorta insufficiency Aortitis Bronchitis Felty's syndrome Heart rhythm disorder	Search
DEBUT DATE	COMORBIDITY	Hemorrhagic alveolitis Inflammatory bowel disease	
01.11.2019	Chronic uveitis	Iridocyclitis/acute ant. uveitis Lymphadenopathy Mononeuritis Other Pericarditis Pleurisy Polyneuronathy	
H ESTABLISH	CEASE CHANGE STATUS	<ul> <li>Psoriasis</li> <li>Pulmonary fibrosis</li> <li>Pulmonary hypertension</li> <li>Raynaud's phenomenon</li> </ul>	
01.11.2019	COMORBIDITY Chronic uveitis	Rheuma nodules Scleritis Secondary amyloidosis Sinusitis	
		Sjögren's syndrome Skin ulcer Subglottic stenosis Vasculitis	
		TOP30 ALL RE	EUMA MANIFESTATIONS
		STATUS COMMENT	ESTABL. I
		3 Verified V	
GROUP ALL	RHEUMA MANIFESTATIONS	DEBUT DATE 01.11.2019 V ONGOING	SAVE AND

#### Graphics



#### Potilaskohtainen data yhteenveto F6

Date	01.11.2019	-
ID	120712A123E	
	ENTESIITTI, EPPU	
Age, Gender	7, Male	
Height	130 cm	
Diagnoses	Juvenile Idiopathic Arthritis	
	IIA Enthesitis Related Arthritis (M081)	
Diagnosis criteria	- Symptoms (ILAR IIA): 01 02 2015	
Diagnosis criceria	- Clinical diagnosis (ILAR IIA): 01.03.2015	
	- Diagnosis date (ILAR IIA): 21.04.2015	
		=
	- Symptoms (Ext. ILAR JIA): 09.04.2018	
	- Clinical diagnosis (Ext. ILAR JIA): 03.06.2019	
	- Diagnosis date (Ext. ILAR JIA): 17.09.2019	
Highest RF (IgM)	Negative 30.03.2015	1
Highest (aCCP)	Negative 30.03.2015	1
Highest ANA	Positive (1280) 30.03.2015	1
Highest SSA	(240) 30.03.2015	1
Highest SSB	(320) 30.03.2015	1
HLA-B27	Positive	1
Drug (used)	Methotrexate 04.05.2015 - 21.04.2016	
	- Adm. method: Peroral	
	- Reason: Adverse effect	
	- Adverse effect: Nausea, Vomiting	
Drug (now)	Etanercept (Enbrel) 25.04.2017	
	- 50,00 mg Subcutaneous Once a week	
	Sulfasalazine 21.04.2016	
	- 2 000.00 mg Peroral Every day	
Vaccination (latest)	- Hepatitis A+B 02.05.2014	1
()	- Other vaccine 01.02.2014	
Comorbidity	- Chronic uveitis 01.11.2019	1
	- Psoriasis 01.11.2019	
Physiotherapy (latest)	22.09.2019 Yes, 4 times a month	1

#### Latest score

Date	15.10.2018	02.04.2019	06.05.2019	17.09.2019	22.09.2019
HEALTH STATUS					
Pain	29		24	45	21
Fatigue	30			30	32
Morning stiffness	0,50		0,00	1,00	0,75
Joint pain	0		14	30	27
Back pain	33			20	36
BOLD STREET				-	

#### Admin/Data extraction/Standard

#### DATA EXTRACTION

PERIOD	GENDER	PATIENT DATA
✓ 01.01.2019 ✓ – 02.11.2019 ✓	BOTH MALE FEMALE	✓ Include patient data
DIAGNOSIS	INTERVENTION	SCORE
Spondyloarthritis	Medication	🕀 🛛 Health status
Osteoarthritis		Disease activity
Septic Arthritis	Etanercept (Enbrel)	
Monoarthritis	<ul> <li>Infliximab (Remicade)</li> </ul>	
Oligoarthritis	Anakinra (Kineret)	5
Polyarthritis	<ul> <li>Adalimumab (Humira)</li> </ul>	
	Rituximab (Mabthera)	
JIA Systemic Arthritis	<ul> <li>Abatacept (Orencia)</li> </ul>	
JIA Oligoarthritis (Persistent)	Certolizumab pegol (Cimzia)	
JIA Oligoarthritis (Extended)	<ul> <li>Tocilizumab (Roactemra)</li> </ul>	
JIA Polyarthritis (RF Negative)	<ul> <li>Golimumab (Simponi)</li> </ul>	
JIA Polyarthritis (RF Positive)	Ustekinumab (Stelara)	
JIA Psoriatic Arthritis	Belimumab (Benlysta)	
JIA Enthesitis Related Arthritis	Infliximab (Inflectra)	
JIA Undifferentiated Arthritis	Infliximab (Remsima)	
Onictal Arthritic	Canakinumab (Ilaris)	-
Juvenile Idiopathic Arthritis	AND OR	

### Admin/Data extraction/Extended data extraction

<b>Q</b> SysAdmin	PATIENT	EXTENDED DATA EXTRACTION	X		_ ×
R Search		EXTRACTION TYPE          STUDY RELATED DATA EXTRACTION       EXTENDED DATA EXTRACTION         EXTENDED DATA EXTRACTION       05.10.2019 \sqcccllllllllllllllllllllllllllllllllll			
		OPTIONS     Exclude patient name and ID number   Include all available diagnosis data   Include all available medication data   Include all available comorbidity data   Include all available injection/infusion data   Include all available surgery data   OBB between   02.11.2003   Include all codes			